Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib‐effective patients with advanced NSCLC

BACKGROUND: Non‐small‐cell lung cancer (NSCLC) is the leading cause of death from cancer in China. Gefitinib is effective for patients with positive epidermal growth factor receptor gene mutation; however, acquired drug resistance counteracts the duration response. Hyperthermia is widely clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Yijia, Sun, Yu, Liu, Yongmei, Luo, Yiqiao, Zhu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930961/
https://www.ncbi.nlm.nih.gov/pubmed/27385984
http://dx.doi.org/10.1111/1759-7714.12346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930961/
https://www.ncbi.nlm.nih.gov/pubmed/27385984
http://dx.doi.org/10.1111/1759-7714.12346

Ejemplares similares